Pretreatment serum albumin level is an independent prognostic factor in patients with stage IIIB non-small cell lung cancer: A study of the Turkish descriptive oncological researches group

Simple item page
dc.contributor.authorTanriverdi O.
dc.contributor.authorAvci N.
dc.contributor.authorOktay E.
dc.contributor.authorKalemci S.
dc.contributor.authorPilanci K.N.
dc.contributor.authorCokmert S.
dc.contributor.authorMenekse S.
dc.contributor.authorKocar M.
dc.contributor.authorSen C.A.
dc.contributor.authorAkman T.
dc.contributor.authorOrdu C.
dc.contributor.authorGoksel G.
dc.contributor.authorMeydan N.
dc.contributor.authorBarutca S.
dc.date.accessioned2024-07-22T08:14:09Z
dc.date.available2024-07-22T08:14:09Z
dc.date.issued2015
dc.description.abstractBackground: Several prognostic factors have been studied in NSCLC, although it is unknown which is most useful. In this study, we aimed to investigate whether pre-treatment serum albumin level has prognostic value in patients with Stage IIIB NSCLC. Materials and Methods: This cross-sectional study included a total of 204 patients with Stage IIIB NSCLC who met the inclusion criteria. Pre-treatment serum albumin levels and demographic, clinical, and histological characteristics, as well as laboratory variables were recorded. A cut-off value was defined for serum albumin level and the patients were stratified into four groups on thios basis. Results: The majority of the patients was males and smokers, with a history of weight loss, and squamous histological type of lung cancer. The mean serum albumin level was 3.2±1.7 g/dL (range, 2.11-4.36 g/dL). A cut-off value 3.11 g/dL was set and among the patients with a lower level, 68% had adenocarcinoma and 82% were smokers. The patients with low serum albumin levels had a lower response rate to e first-line chemotherapy with a shorter progression-free survival and overall survival. Multivariate analysis showed that low serum albumin level was an independent poor prognostic factor for NSCLC. Conclusions: This study results suggest that low serum albumin level is an independent poor prognostic factor in patients with Stage IIIB NSCLC, associated with reduction in the response rate to first-line therapy and survival rates.
dc.identifier.DOI-ID10.7314/APJCP.2015.16.14.5971
dc.identifier.issn15137368
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16488
dc.language.isoEnglish
dc.publisherAsian Pacific Organization for Cancer Prevention
dc.rightsAll Open Access; Gold Open Access
dc.subjectAdenocarcinoma
dc.subjectAged
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBiomarkers, Tumor
dc.subjectCarcinoma, Adenosquamous
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectCarcinoma, Squamous Cell
dc.subjectCross-Sectional Studies
dc.subjectEnzyme-Linked Immunosorbent Assay
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectLung Neoplasms
dc.subjectLymphatic Metastasis
dc.subjectMale
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectRetrospective Studies
dc.subjectSerum Albumin
dc.subjectSurvival Rate
dc.subjectTurkey
dc.subjectantineoplastic agent
dc.subjectserum albumin
dc.subjecttumor marker
dc.subjectadenocarcinoma
dc.subjectaged
dc.subjectblood
dc.subjectcancer staging
dc.subjectCarcinoma, Adenosquamous
dc.subjectCarcinoma, Non-Small-Cell Lung
dc.subjectCarcinoma, Squamous Cell
dc.subjectcross-sectional study
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectLung Neoplasms
dc.subjectlymph node metastasis
dc.subjectmale
dc.subjectmortality
dc.subjectpathology
dc.subjectprognosis
dc.subjectretrospective study
dc.subjectsecondary
dc.subjectsurvival rate
dc.subjectTurkey
dc.titlePretreatment serum albumin level is an independent prognostic factor in patients with stage IIIB non-small cell lung cancer: A study of the Turkish descriptive oncological researches group
dc.typeArticle

Files

Collections

Scopus Koleksiyonu